Are Corcept Therapeutics Inc (CORT) stocks a prudent buy?

At the time of writing, Corcept Therapeutics Inc [CORT] stock is trading at $60.85, up 1.98%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CORT shares have gain 3.88% over the last week, with a monthly amount glided 21.55%, and seem to be holding up well over a long-time horizon.

From an analyst’s perspective:

Corcept Therapeutics Inc [NASDAQ: CORT] stock has seen the most recent analyst activity on November 06, 2023, when Truist upgraded its rating to a Buy and also boosted its price target to $38 from $29. Previously, SVB Securities started tracking the stock with Market Perform rating on April 11, 2023, and set its price target to $25. On April 04, 2023, Piper Sandler initiated with a Overweight rating and assigned a price target of $27 on the stock. Jefferies downgraded its rating to a Hold and decreased its price target to $22 on February 15, 2023. Truist downgraded its rating to a Hold but $30 remained the price target by the analyst firm on August 01, 2022. Jefferies upgraded its rating to Buy for this stock on July 27, 2022, and upped its price target to $35.

For the past year, the stock price of Corcept Therapeutics Inc fluctuated between $20.84 and $61.66. Currently, Wall Street analysts expect the stock to reach $68 within the next 12 months. Corcept Therapeutics Inc [NASDAQ: CORT] shares were valued at $60.85 at the most recent close of the market. An investor can expect a potential return of 11.75% based on the average CORT price forecast.

Analyzing the CORT fundamentals

According to Corcept Therapeutics Inc [NASDAQ:CORT], the company’s sales were 628.55M for trailing twelve months, which represents an 47.69% jump. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at 0.23%, Pretax Profit Margin comes in at 0.26%, and Net Profit Margin reading is 0.22%. To continue investigating profitability, this company’s Return on Assets is posted at 0.18, Equity is 0.25 and Total Capital is 0.22. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 59.51 points at the first support level, and at 58.18 for the second support level. However, for the 1st resistance point, the stock is sitting at 62.20, and for the 2nd resistance point, it is at 63.56.

Ratios To Look Out For

It is important to note that Corcept Therapeutics Inc [NASDAQ:CORT] has a current ratio of 3.70. Also, the Quick Ratio is 3.64, while the Cash Ratio stands at 1.09. Considering the valuation of this stock, the price to sales ratio is 10.14, the price to book ratio is 9.97 and price to earnings (TTM) ratio is 48.39.

Transactions by insiders

Recent insider trading involved Robb Gary Charles, Chief Business Officer, that happened on Nov 22 ’24 when 2609.0 shares were sold., Lyon Joseph Douglas completed a deal on Nov 22 ’24 to sell 1411.0 shares. Meanwhile, Officer Lyon Joseph Douglas bought 1411.0 shares on Nov 22 ’24.

Related Posts